Idiopathic pulmonary fibrosis: Current and future treatment
DS Glass, D Grossfeld, HA Renna… - The clinical …, 2022 - Wiley Online Library
Objectives Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease characterized
by dry cough, fatigue, and progressive exertional dyspnea. Lung parenchyma and …
by dry cough, fatigue, and progressive exertional dyspnea. Lung parenchyma and …
Idiopathic pulmonary fibrosis: state of the art for 2023
AJ Podolanczuk, CC Thomson… - European …, 2023 - Eur Respiratory Soc
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease characterised by
worsening respiratory symptoms and physiological impairment. Increasing awareness of the …
worsening respiratory symptoms and physiological impairment. Increasing awareness of the …
Idiopathic pulmonary fibrosis
DJ Lederer, FJ Martinez - New England Journal of Medicine, 2018 - Mass Medical Soc
Idiopathic Pulmonary Fibrosis | New England Journal of Medicine Skip to main content The
New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …
New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
TM Maher, ME Strek - Respiratory research, 2019 - Springer
Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a dismal prognosis. The
average life expectancy of untreated patients with IPF is only 3 to 4 years. Decline in forced …
average life expectancy of untreated patients with IPF is only 3 to 4 years. Decline in forced …
The therapy of idiopathic pulmonary fibrosis: what is next?
V Somogyi, N Chaudhuri, SE Torrisi… - European …, 2019 - Eur Respiratory Soc
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung
disease, characterised by progressive scarring of the lung and associated with a high …
disease, characterised by progressive scarring of the lung and associated with a high …
Progressive pulmonary fibrosis: an expert group consensus statement
This expert group consensus statement emphasises the need for standardising the definition
of progressive fibrosing interstitial lung diseases (F-ILDs), with an accurate initial diagnosis …
of progressive fibrosing interstitial lung diseases (F-ILDs), with an accurate initial diagnosis …
Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study
Background Idiopathic interstitial pneumonias are often complicated by pulmonary
hypertension, increasing morbidity and mortality. There are no approved treatments for …
hypertension, increasing morbidity and mortality. There are no approved treatments for …
[HTML][HTML] Physiology of the lung in idiopathic pulmonary fibrosis
L Plantier, A Cazes, AT Dinh-Xuan… - European …, 2018 - Eur Respiratory Soc
The clinical expression of idiopathic pulmonary fibrosis (IPF) is directly related to multiple
alterations in lung function. These alterations derive from a complex disease process …
alterations in lung function. These alterations derive from a complex disease process …
Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals
HM Al-Kuraishy, GES Batiha, H Faidah… - …, 2022 - Springer
Pirfenidone (PFN) is an anti-fibrotic drug with significant anti-inflammatory property used for
treatment of fibrotic conditions such as idiopathic pulmonary fibrosis (IPF). In the coronavirus …
treatment of fibrotic conditions such as idiopathic pulmonary fibrosis (IPF). In the coronavirus …
Discharge may not be the end of treatment: pay attention to pulmonary fibrosis caused by severe COVID‐19
C Zhang, Z Wu, JW Li, K Tan, W Yang… - Journal of medical …, 2021 - Wiley Online Library
Since December 2019, coronavirus disease (COVID‐19) has rapidly swept the world. So far,
more than 30 million people have been infected and nearly one million have died. Although …
more than 30 million people have been infected and nearly one million have died. Although …